OCA
AKRO

Octagon Capital Advisors’s Akero Therapeutics AKRO Stock Holding History

Octagon Capital Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-283,372
Closed -$6.65M – 44
2024
Q2 		$6.65M Sell
283,372
-56,628
-17% -$1.21M 1.04% 27
2024
Q1 		$8.59M Buy
+340,000
New +$8.17M 1.03% 29
2022
Q4 		– Sell
-75,000
Closed -$2.55M – 34
2022
Q3 		$2.55M Buy
+75,000
New +$1.15M 0.44% 28

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Octagon Capital Advisors's AKRO Position: Q3 2024 in Review

Octagon Capital Advisors sold out of Akero Therapeutics (AKRO) in Q3 2024, closing a stake of 283,372 shares — an estimated $6.65M sold.

Octagon Capital Advisors first reported a position in AKRO in Q3 2022 and held it in 3 quarters. The position peaked at $8.59M in Q1 2024. 168 funds tracked by Wall St. Rank hold AKRO as of Q3 2024.

  • Octagon Capital Advisors reported no remaining Akero Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 283,372 Akero Therapeutics shares in Q3 2024, an estimated $6.65M.
  • Octagon Capital Advisors first reported a position in Akero Therapeutics in Q3 2022 and held it in 3 quarters.
  • Octagon Capital Advisors's Akero Therapeutics position peaked at $8.59M in Q1 2024.
  • 168 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2024.

Based on Octagon Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.